Nachman, S., Alvero, C., Teppler, H., Homony, B., Rodgers, A. J., Graham, B. L., . . . Wiznia, A. A. (2018). Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: A phase 1/2 open label, non-randomised, multicentre trial. Lancet HIV.
Chicago-stil citatNachman, Sharon, et al. "Safety and Efficacy At 240 Weeks of Different Raltegravir Formulations in Children With HIV-1: A Phase 1/2 Open Label, Non-randomised, Multicentre Trial." Lancet HIV 2018.
MLA-referensNachman, Sharon, et al. "Safety and Efficacy At 240 Weeks of Different Raltegravir Formulations in Children With HIV-1: A Phase 1/2 Open Label, Non-randomised, Multicentre Trial." Lancet HIV 2018.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.